Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

常茂生物化學工程股份有限公司

Changmao Biochemical Engineering Company Limited*

(a joint stock limited company incorporated in the People's Republic of China)

(Stock Code: 954)

PROFIT ALERT – REDUCTION IN LOSS

This announcement is made by Changmao Biochemical Engineering Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the "**Board**") wishes to inform the shareholders of the Company and potential investors that having assessed the currently available information, the Group is expected to record a consolidated net loss attributable to shareholders of the Company in the range of RMB4 million to RMB6 million for the six months ended 30 June 2026, representing a significant narrowing from the consolidated net loss attributable to shareholders of the Company of RMB25,790,000 for the six months ended 30 June 2025.

For identification purpose only

The Board believes that the improvement in the Group’s financial performance for the six months ended 30 June 2026 was primarily attributable to the following factors:

(1) in response to market demand, the Group optimized its product structure and expanded the production capacity of relevant products, thereby driving growth in both revenue and gross profit; and

(2) the market for products from the phase II production line of the Company's subsidiary, Changmao (Dalian) New Material Company Limited, is progressively expanding, leading to a narrowing of net losses.

As the Company is still in the process of finalising the results of the Group for the six months ended 30 June 2026, the information contained in this announcement is a preliminary assessment by the Board with reference to the management accounts of the Group and the information currently available to the Company. Such information has not been audited or reviewed by the Company’s auditor and/or the audit committee. Further details of the Group’s performance will be disclosed when the Group’s results for the six months ended 30 June 2026 are announced, which is expected to be on 18 August 2026.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Changmao Biochemical Engineering Company Limited*
Rui Xin Sheng
Chairman

The PRC, 3 August 2026

As at the date hereof, Mr. Rui Xin Sheng (Chairman), Mr. Pan Chun and Ms. Rui Xiao Qian are the executive directors of the Company, Mr. Yu Xiao Ping, Ms. Leng Yi Xin and Mr. Lin Ze Yu are the non-executive directors of the Company, Mr. Zhou Zhi Wei, Mr. Shu Rong Xin and Ms. Cheng Mun Wah are the independent non-executive directors of the Company.

**For identification purpose only*